We rarely see headline stories about sepsis and how devastating this illness actually is. Sepsis kills more people every year than breast cancer, prostate cancer, and HIV/AIDS combined. In fact, it is the most common cause of deaths in the United States, out-pacing heart attacks and strokes. There are more than 1 million sepsis diagnosis in the USA each year, and up to half of those patients will die. Despite many decades of research and drug development, there have been very few mediator-specific treatments that consistently improve survival of sepsis patients. Physicians still have to rely in most cases on conventional supportive measures and antibiotics to save lives. We are changing the paradigm by leveraging combination therapies in order to bring cures to the market with significant unmet medical need.

Our clinical-stage drug program for reprogramming immune cells is a novel IV therapeutic designed to reprogram neutrophils metabolism back to homeostasis for patients with both sepsis and septic shock. These hyperactive immune cells and their redox signaling pathways contribute significantly to the severity of sepsis multiple organ failure.